The GSK3B Knockout Jurkat Polyclonal Cells consist of a CRISPR/Cas9-edited polyclonal knockout cell population derived from the Jurkat human T lymphocyte leukemia line, with disruption of the GSK3B gene. This polyclonal format avoids clonal selection artifacts, offering a robust, heterogeneous model for investigating GSK3B-dependent mechanisms across diverse cellular contexts.
Jurkat cells are immortalized T lymphocytes that recapitulate T cell receptor (TCR) signaling, activation, and apoptosis. Their well-defined signaling networks and ease of culture make them a premier model for immunological studies, cancer biology, and signal transduction research, particularly for dissecting pathways that control T cell fate.
GSK3B encodes glycogen synthase kinase 3 beta, a constitutively active serine/threonine kinase that phosphorylates substrates including ??-catenin, c-Myc, and Cyclin D1, often promoting ubiquitin-dependent degradation. In the Wnt pathway, ligands (e.g., WNT3A) bind Frizzled and LRP5/6 co-receptors, activating Dishevelled to inhibit the Axin-APC-GSK3B destruction complex, leading to ??-catenin accumulation and TCF/LEF-dependent transcription. Insulin and PI3K/AKT signaling inhibit GSK3B by phosphorylation at Ser9, while PKA, PKC, and mTOR provide additional regulatory inputs. GSK3B also interacts with FRAT1 and PP2A, and its downstream targets include NFAT, Snail, Tau, and MCL1, positioning it as a critical node in cell proliferation, survival, and metabolism.
In Jurkat T cells, GSK3B intersects with TCR and Wnt/??-catenin pathways to modulate activation, proliferation, and apoptosis. Disruption of GSK3B alters ??-catenin transcriptional programs and T cell activation marker expression, offering a means to study the kinase??s role in leukemic T cell biology. These polyclonal knockout cells are particularly useful for exploring how GSK3B integrates signals from NF-??B and PI3K-Akt pathways, which are frequently dysregulated in cancer and inflammation.
These cells are designed for high-resolution assays including phospho-GSK3B (Ser9) Western blotting, ??-catenin/TCF luciferase reporter analysis, and flow cytometry for T cell activation markers (e.g., CD69, CD25). Applications extend to co-immunoprecipitation of Axin-GSK3B complexes, RT-qPCR profiling of Wnt target genes (MYC, CCND1), and apoptosis evaluation via Annexin V/PI staining. They support cancer drug target validation, insulin signaling and glucose metabolism research, and neurodegeneration studies focused on Tau phosphorylation. For detailed technical support and ordering, please contact Ascent Research.
